Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of a novel schedule of an oral
anticancer drug, capecitabine, in patients with metastatic breast cancer.
Mathematical models have predicted that 7 days of capecitabine followed by 7 days of rest is
an optimal dosing schedule for this drug and previous studies done al Memorial Sloan
Kettering Cancer Center support the tolerability of this scheme.
This definitive, randomized trial comparing the efficacy of the new dosage with the
conventional dosing schedule in patients with metastatic breast cancer is necessary and we
hypothesize it will be superior in terms of efficacy.
Dosing schedules based on mathematical predictions for optimal drug delivery based on
efficacy rather than toxicity could facilitate more rapid and economical drug development.
This trial is a proof of principle trial of the highest priority.
Phase:
N/A
Details
Lead Sponsor:
Latin American & Caribbean Society of Medical Oncology